These authors contributed equally to this work. Dr. Yongmei Ji is currently affiliated with University of Chicago Booth School of Business, Chicago, IL; Dr. Bruce Taillon is currently affiliated with Enzo Life Sciences, Farmingdale, NY; Dr. David C. Swinney is currently affiliated with iRND3, Institute for Rare and Neglected Diseases Drug Discovery, Belmont, CA; Dr. Simon Fletcher and Dr. Uri Lopatin are currently affiliated with Gilead Science, Foster City, CA.
Version of Record online: 12 JUL 2012
Copyright © 2012 American Association for the Study of Liver Diseases
Volume 56, Issue 3, pages 820–830, September 2012
How to Cite
Fletcher, S. P., Chin, D. J., Ji, Y., Iniguez, A. L., Taillon, B., Swinney, D. C., Ravindran, P., Cheng, D. T., Bitter, H., Lopatin, U., Ma, H., Klumpp, K. and Menne, S. (2012), Transcriptomic analysis of the woodchuck model of chronic hepatitis B. Hepatology, 56: 820–830. doi: 10.1002/hep.25730
Potential conflict of interest: A. Leonardo Iniguez is an employee of Roche NimbleGen, the corporation which generated (and may commercialize) the custom woodchuck microarray. Dr. Fletcher is employed by Roche. Dr. Chin is employed by and owns stock and intellectual property rights in Roche. Dr. Taillon is employed by Roche. Dr. Chen is employed by Roche. Dr. Ma is employed by Roche. Dr. Klumpp is employed by Roche.
The complete woodchuck transcriptome data are available at the NCBI SRA under accession number SRA050380 and the microarray data have been deposited in the NCBI GEO under accession number GSE36250.
- Issue online: 28 AUG 2012
- Version of Record online: 12 JUL 2012
- Accepted manuscript online: 20 MAR 2012 12:00AM EST
- Manuscript Accepted: 6 MAR 2012
- Manuscript Received: 24 JAN 2012
- College of Veterinary Medicine, Cornell University. Grant Number: N01-AI-05399
- National Institute of Allergy and Infectious Diseases (NIAID)
- 9Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Statist Soc Ser B (Methodological) 1995; 57: 289‒300., .
- 16Blocking chemokine responsive to gamma-2/interferon (IFN)-gamma inducible protein and monokine induced by IFN-gamma activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus-specific cytotoxic T lymphocytes. J Exp Med 2001; 194: 1755‒1766., , , , , , et al.